Physician profile
David Szuster
NPI 1083721245
$14,934.86
in general payments reported to CMS, 2019-2025
22 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,958 · 2020: $2,490 · 2021: $1,618 · 2022: $1,023 · 2023: $1,885 · 2024: $2,930 · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,774 · Education: $72.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,774.22 |
| Education | $72.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,556.12 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,101.06 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,871.84 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $1,625.57 | 2019-2025 | Lybalvi, Aristada |
| Allergan, INC. | $1,579.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $1,202.34 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $924.19 | 2019-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $762.32 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $564.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.18 | 2020-2024 | Trintellix |
| Corium, LLC | $284.85 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $279.29 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $205.52 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $157.00 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $110.79 | 2023-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cognoa, INC. | $83.49 | 2022 | |
| Vanda Pharmaceuticals INC. | $56.64 | 2023 | Hetlioz, Fanapt |
| Biogen, INC. | $53.62 | 2024 | |
| Ironshore Pharmaceuticals INC. | $44.19 | 2019 | |
| Merck Sharp & Dohme LLC | $41.76 | 2020 | |
| Collegium Pharmaceutical, INC. | $24.09 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $19.83 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Szuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.